Chlorogenic Acid‐Conjugated Nanoparticles Suppression of Platelet Activation and Disruption to Tumor Vascular Barriers for Enhancing Drug Penetration in Tumor

Yue Ke,Zhifang Ma,Hongbo Ye,Xinghua Guan,Zehong Xiang,Yu Xia,Qiang Shi
DOI: https://doi.org/10.1002/adhm.202202205
IF: 10
2022-12-14
Advanced Healthcare Materials
Abstract:Hypercoagulation threatens the lives of cancer patients and cancer progression. Platelet over‐activation attributes to the tumor‐associated hypercoagulation and maintenance of the tumor endothelial integrity, leading to limited intratumoral perfusion of nanoagents into solid tumors in spite of the enhanced penetration and retention effect (EPR). Therefore, the clinical application of nanotherapeutics in solid cancer still faces great challenges. Herein, we established a platelet inhibiting nanoagents based on FeIII‐doped C3N4 co‐loaded with the chemotherapy drug and the antiplatelet drug chlorogenic acid (CA), further opening tumor vascular endothelial junctions, thereby disrupting the tumor vascular endothelial integrity, and enhancing drug perfusion. Moreover, CA not only damages the cancer cells but also potentiates the cytotoxicity induced by the chemotherapy drug doxorubicin, synergistically ablating the tumor tissue. Further, the introduction of CA relieves the original causes of the hypercoagulable state such as tissue factor (TF), thrombin and matrix metalloproteinases (MMPs) secreted by cancer cells. We anticipate that the hypercoagulation‐ and platelet‐inhibition strategy by integration of phenolic acid CA into chemotherapy provides insights into platelet inhibition‐assisted theranostics based on nanomedicines. This article is protected by copyright. All rights reserved
nanoscience & nanotechnology,engineering, biomedical,materials science, biomaterials
What problem does this paper attempt to address?